Clozapine N-oxide (CNO): Chemogenetic Guide
2026-08-28
Clozapine N-oxide (CNO) is a research metabolite and chemogenetic actuator used with engineered muscarinic DREADDs. Its main value is reversible neuronal activity modulation, while receptor expression, clozapine conversion, solubility, and experimental controls determine how results should be interpreted.
Rottlerin and Clathrin-Mediated GCRV Entry
2026-08-27
Wang et al. used pharmacological inhibition, transmission electron microscopy, and RT-qPCR to show that genotype III grass carp reovirus enters CIK cells through a dynamin-dependent, clathrin-mediated, pH-sensitive pathway. The study positions Rottlerin as a useful pathway probe because it inhibited GCRV104 entry and replication, while also emphasizing that inhibitor data should be interpreted with orthogonal assays.
Toremifene Workflows for Prostate Cancer Research
2026-08-27
Toremifene provides a practical selective estrogen-receptor modulator framework for connecting hormone-responsive phenotypes with migration, invasion, and calcium-signaling assays. This workflow-oriented guide shows how to benchmark growth inhibition while testing whether estrogen receptor modulation intersects with the TSPAN18–STIM1 axis described in prostate cancer metastasis research.
NVP-BGJ398 phosphate: FGFR Workflow Guide
2026-08-26
NVP-BGJ398 phosphate combines potent FGFR1–3 inhibition with a workflow that connects phospho-signaling, genotype, cell phenotype, and tissue-level outcomes. This guide shows how to use BGJ-398 phosphate in biomarker-led cancer studies and FGFR3-focused skeletal disease models while avoiding common assay and formulation errors.
Anlotinib hydrochloride in Angiogenesis Workflows
2026-08-26
Build more informative angiogenesis experiments by pairing Anlotinib hydrochloride with migration, tube formation, receptor-phosphorylation, and pathway-readout assays. Its coordinated activity against VEGFR2, PDGFRβ, and FGFR1 helps distinguish broad angiogenic signaling suppression from single-pathway effects.
DMXAA (Vadimezan) Workflows for Tumor Vascular Studies
2026-08-25
DMXAA (Vadimezan) enables mechanism-guided studies of tumor endothelial apoptosis, VEGFR2-linked angiogenesis, and vascular disruption. This practical workflow also shows how to compare direct vascular injury with the vessel-normalization and immune-infiltration model emerging from endothelial STING-JAK1 research.
Fluoxetine HCl: From Assay Signal to Behavior
2026-08-25
Fluoxetine HCl is a selective serotonin reuptake inhibitor used to connect serotonin transporter pharmacology with 5HT2C physiology and behavioral neuroscience. This guide presents an endpoint-aware framework for interpreting neurogenesis, synaptic plasticity, motivation, and stress resilience experiments without conflating molecular activity with therapeutic outcome.
6-FAM SE: Reliable Fluorescent Labeling
2026-08-24
A scenario-driven guide to using 6-FAM SE (6-Carboxyfluorescein N-hydroxysuccinimide ester), SKU A8771, for more controlled labeling of DNA, proteins, peptides, and assay-tracking reagents. It addresses compatibility, solubility, storage, interpretation, and vendor-selection decisions without presenting the dye as a substitute for validated cell-viability endpoints.
Pseudo-UTP: Engineering Better mRNA Translation
2026-08-23
Pseudo-modified uridine triphosphate provides a controllable route to pseudouridine-modified RNA, with implications for RNA stability enhancement, translation performance, and innate immune signaling. This thought-leadership analysis connects Pseudo-UTP chemistry to the translational lessons of a MERS-CoV RBD-mRNA vaccine study while distinguishing product-specific evidence from broader nucleoside-modification principles.
Anlotinib Hydrochloride: Assay Workflows
2026-08-22
Build reproducible angiogenesis experiments around Anlotinib hydrochloride, from receptor phosphorylation to endothelial migration and tube formation. This workflow separates pathway-specific anti-angiogenic activity from direct tumor-cell toxicity, helping cancer research teams select informative concentrations and controls.
Dacarbazine: From DNA Damage to Translation
2026-08-21
A translational framework for using Dacarbazine with greater mechanistic precision—from DNA alkylation and assay design to regimen context, supportive care, and reproducibility.
GSK2606414: A Practical PERK Inhibitor Workflow
2026-08-21
GSK2606414 combines nanomolar PERK potency with strong kinase selectivity, making it useful for separating PERK-dependent unfolded protein response signaling from broader ER-stress effects. This guide translates recent pyroptosis findings into practical workflows for ER stress research, cancer research, and disease-model validation.
BRD4-Targeted PROTAC Nanoassemblies Enhance FLASH-RT
2026-08-20
Xu and colleagues developed a folate-targeted, redox-responsive PROTAC nanoassembly that releases ARV-771 inside tumor cells and promotes BRD4 degradation during FLASH radiotherapy. The resulting disruption of BRD4-associated DNA repair, together with increased reactive oxygen species and DNA double-strand breaks, improved tumor cell killing in vitro and in vivo with limited systemic toxicity in the reported preclinical models.
ECL Chemiluminescent Substrate Detection Kit Workflow
2026-08-20
Build a sensitive, flexible immunoblot workflow for low-abundance targets using HRP-mediated signal generation on nitrocellulose or PVDF. This guide connects the kit to the urinary nanosensor findings in early atherosclerosis research while clearly separating protein validation from activity-based and diagnostic assays.
ZNF263–ULK1 Autophagy Axis in Cholangiocarcinoma
2026-08-19
This study identifies ZNF263 as an oncogenic transcription factor in intrahepatic cholangiocarcinoma (ICC) and links its activity to enhancer-mediated activation of ULK1 and autophagy. By integrating genomic profiling, reporter assays, cellular phenotyping, and xenograft experiments, the authors provide a mechanistic framework for how ZNF263 may support ICC proliferation.
458 records 7/31 page Previous Next First page 上5页 678910 下5页 Last page